Sellas Life Sciences has dosed the first paediatric subject with acute myeloid leukaemia (AML) in its multi-centre Phase II ...

Interestingly, some viral protein kinases in herpesviruses are structurally conserved and mimic human cyclin-dependent kinases (CDKs). Herpes simplex virus 2 (HSV-2) causes skin and genital ...

To demonstrate DiffSMol's abilities, researchers conducted case studies on molecules used in two crucial drug targets, one ...

Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

Researchers have introduced DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules ...

Cyclin-dependent kinase inhibitor 1A (CDKN1A) is consistently upregulated in metabolic dysfunction-associated steatotic liver disease (MASLD) and correlates with disease severity, activity score ...

The company's lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin ...

Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ...